RxDoctor Payments Data

Lauren Cameron, MD

Neurology · Parma, OHNPI 1891054466

Payments from drug & device makers

$7,033in general payments, 2019–2025

Across 414 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$725
  • Teva Pharmaceuticals USA, Inc.$716
  • Neurocrine Biosciences, Inc.$422
  • SK Life Science, Inc.$314
  • Genentech USA, Inc.$305
  • plus $3K from 40 others

What the payments were for

  • Speaking & faculty fees$1472%
  • Food & beverage$6,68395%
  • Education$2033%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,033 in reported general payments places this provider in the 65th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$237,354
Medicare patients
432
Services billed
19,790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate71$595,633
AustedoDeutetrabenazine30$346,983
Austedo XrDeutetrabenazine35$223,511
NuplazidPimavanserin Tartrate35$215,141
RytaryCarbidopa/Levodopa49$95,917
Carbidopa-LevodopaCarbidopa/Levodopa716$23,976
Rasagiline Mesylate67$19,523
UbrelvyUbrogepant13$17,713
Emgality PenGalcanezumab-Gnlm14$11,237
Primidone314$7,940
AmantadineAmantadine Hcl169$7,891
Ropinirole ErRopinirole Hcl39$7,253
Carbidopa-Levodopa ErCarbidopa/Levodopa217$7,198
RivastigmineRivastigmine Tartrate76$6,523
Memantine Hcl125$4,325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$422$595,63371 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$716$570,49465 claims
Acadia Pharmaceuticals IncNuplazid$103$215,14135 claims
Amneal Pharmaceuticals LLCRytary$110$95,91749 claims
AbbVieUbrelvy$1,068$17,71313 claims
Upsher-smith Laboratories LLCTopiramate$43$1,48289 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 702 neurology providers in Ohio.

Other neurology in Parma

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →